# US 8,541,670 B2 · Compositions and methods for inhibiting tumor cell growth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,670 B2
- Document ID: US8541670B2
- Status: Granted
- Kind: B2
- Application number: 12/560,914
- Filed: 2009-09-16
- Published: 2010-02-25
- Granted: 2013-09-24
- Earliest claimed: 2007-03-21
- Applicants: Effat Emamian
- Inventors: Effat Emamian
- Web page: https://patentgrep.com/patent/US8541670B2

## CPC

- C07K 7/00: Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to compositions and methods for inhibiting the activity of an enzyme, for example, Protein Kinase B, p70S6K and/or Abl using the catalytic subunit of Protein Kinase A (PKAc), or at least one PKAc fragment or variant PKAc fragment thereof. In this regard, methods for preventing or treating cancer or a neurodegenerative disease or disorder are also provided.

## Claims

### Claim 1

A composition comprising one or more peptide(s), wherein the peptide(s) is a PKAc fragment or variant thereof selected from the group consisting of;
(a) the peptide of SEQ ID NO: 60; and
(b) a peptide variant that has at least 40% identity with SEQ ID NO: 60 and inhibits human AKT1.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the peptide variant comprises an arginine substitution at position 14 and/or 17 of SEQ ID NO: 60.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the peptide or peptide variant is comprised within a fusion protein having additional peptide(s) or polypeptide(s) located at the N- and/or C-terminus of the peptide or peptide variant.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the peptide or peptide variant further comprises an amino acid modification selected from the group consisting of phosphorylation, acetylation, and methylation.

### Claim 5 (depends on 1)

An in vitro or cell culture method for inhibiting the activity of AKT1 or p70S6K using the composition of claim 1.

### Claim 6 (depends on 1)

A cell culture method for inhibiting cell proliferation using the composition of claim 1.

### Claim 7 (depends on 1)

The composition of claim 1, further comprising a carrier, wherein the carrier allows for the controlled, local release of the therapeutic peptide(s).

### Claim 8 (depends on 1)

The composition of claim 1, wherein the peptide is as set forth by SEQ ID NO: 60.